- Home
- SEED vs NCEL Comparison
SEED vs NCEL Comparison
Compare SEED & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | NCEL |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | China | Switzerland |
| Employees | N/A | 11 |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 13.2M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | SEED | NCEL |
|---|---|---|
| Price | $1.09 | $2.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 109.3K | 17.2K |
| Earning Date | 01-30-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $1.89 |
| 52 Week High | $2.49 | $4.70 |
Technical Indicators
Market Signals| Indicator | SEED | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 37.58 |
| Support Level | $0.96 | $2.44 |
| Resistance Level | $1.30 | $3.16 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 10.64 | 2.70 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.